Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma
Study Details
Study Description
Brief Summary
This study is designed to evaluate the efficacy and safety of tislelizumab and tislelizumab in combination with investigational agent(s) in first-line recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 2 |
Detailed Description
This study will test whether tislelizumab alone and combined with other investigational agents can be used to improve treatment outcomes in participants with head and neck squamous cell carcinoma. The main goals of the study are to determine how many participants may no longer have evidence of cancer or have some improvement in the signs and symptoms of cancer after treatment and to determine what adverse events, or side effects, participants might experience.
Tislelizumab is used to block the programmed cell death protein-1 pathway so that immune system cells (T-cells) can better protect the body from infection and find tumor cells to attack. Tislelizumab may be used in combination with other therapies as a promising approach with potential therapeutic benefits to treat participants with cancer. The study will enroll approximately 160 participants. Participants will be randomly assigned (by chance, similar to flipping a coin) to one of the various treatment groups. Tislelizumab and investigational agents will be administered as an infusion through a vein at regularly scheduled intervals.
The study will take place at multiple centers worldwide. Treatments will continue until participants experience no benefits, too many side effects, or withdraw consent.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: Tislelizumab Tislelizumab 200 milligrams (mg) administered once every 3 weeks |
Drug: Tislelizumab
Administered intravenously
Other Names:
|
| Experimental: Tislelizumab + BGB-A425 Tislelizumab 200 mg administered once every 3 weeks with BGB-A425 |
Drug: Tislelizumab
Administered intravenously
Other Names:
Drug: BGB-A425
Administered intravenously
|
| Experimental: Tislelizumab + LBL-007 Tislelizumab 200 mg administered once every 3 weeks with LBL-007 |
Drug: Tislelizumab
Administered intravenously
Other Names:
Drug: LBL-007
Administered intravenously
|
| Experimental: Tislelizumab + BGB-A425 + LBL-007 Tislelizumab 200 mg administered once every 3 weeks with BGB-A425 and LBL-007 |
Drug: Tislelizumab
Administered intravenously
Other Names:
Drug: BGB-A425
Administered intravenously
Drug: LBL-007
Administered intravenously
|
Outcome Measures
Primary Outcome Measures
- Objective Response Rate (ORR) [Up to approximately 3 years and 6 months]
ORR is defined as percentage of participants who have a confirmed complete response (CR) or a confirmed partial response (PR) as assessed by the investigators using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Secondary Outcome Measures
- Progression-free Survival (PFS) [Up to approximately 3 years and 6 months]
PFS is defined as the time from the date of randomization to the date of the first documentation of progressive disease assessed by the investigators per RECIST v1.1 or death, whichever occurs first
- Duration of Response (DOR) [Up to approximately 3 years and 6 months]
DOR is defined as the time from the first determination of a confirmed response per RECIST v1.1 until the first documentation of progression or death, whichever occurs first
- Clinical Benefit Rate (CBR) [Up to approximately 3 years and 6 months]
CBR is defined as the percentage of participants with a best overall response of a confirmed CR, a confirmed PR, or a durable stable disease (SD) (SD duration ≥ 24 weeks)
- Disease Control Rate (DCR) [Up to approximately 3 years and 6 months]
DCR is defined as the percentage of participants with a best overall response of a confirmed CR, a confirmed PR, or SD
- Number of Participants with Adverse Events [Up to approximately 3 years and 6 months]
Number of participants with adverse events, including laboratory values, vital signs, physical examinations, and electrocardiogram findings
- Overall Survival (OS) [Up to approximately 3 years and 6 months]
OS is defined as the time from the date of randomization to the date of death due to any cause
- Number of Participants with Anti-Drug Antibodies (ADAs) [Up to approximately 3 years and 6 months]
Number of participants with detectable ADAs
Eligibility Criteria
Criteria
Inclusion Criteria:
- Participants with histologically or cytologically confirmed R/M HNSCC that is considered incurable by local therapies
-
The eligible primary tumor locations are oropharynx, oral cavity, hypopharynx, and larynx
-
Participants should not have had prior systemic therapy administered in the R/M setting; systemic therapy which was completed prior to randomization/enrollment if given as part of multimodal treatment for locally or locoregionally advanced disease is allowed
-
Participants must have positive PD-L1 expression (Combined Positive Score [CPS] ≥ 1)
-
Have at least 1 measurable lesion as defined per RECIST v1.1
-
Eastern Cooperative Oncology Group Performance Status of 0 or 1
-
Adequate hematologic and organ function as indicated by specific laboratory values within 7 days of first dose of study drug
-
Willing to use a highly effective method of birth control for the duration of the study and for ≥ 120 days after the last dose of study drug(s)
Exclusion Criteria:
-
Recurrent or metastatic carcinoma of the nasopharynx (any histology), squamous cell carcinoma of unknown primary, squamous cell carcinoma that originated from the skin and salivary gland primary tumor or non-squamous histologies (eg, mucosal melanoma)
-
Prior therapy with an anti-PD-1, anti-PD-L1, PD-L2, T-cell immunoglobulin and mucin domain containing-3 (TIM-3), LAG-3, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways
-
Any active malignancy ≤ 2 years before randomization/enrollment except for the specific cancer under investigation in this study, those with a negligible risk of metastasis or death, and any locally recurring cancer that has been treated curatively (eg, resected basal or squamous cell skin cancer, superficial bladder cancer, localized prostate cancer, and carcinoma in situ of the cervix or breast)
-
History of interstitial lung disease, noninfectious pneumonitis, or uncontrolled lung diseases including pulmonary fibrosis, and acute lung diseases
-
A history of severe hypersensitivity reactions to other monoclonal antibodies or has experienced a severe immune-mediated adverse event (imAE), an imAE that led to treatment discontinuation, or a cardiac or ocular imAE of any grade with prior immunotherapy
Note: Other inclusion and exclusion criteria may apply
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- BeiGene
Investigators
- Study Director: Study Director, BeiGene
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- BGB-HNSCC-201